“The Applicant evaluated the safety of cemiplimab in cynomolgus monkeys in GLP-compliant repeat-dose toxicology studies of up to 26 weeks duration.”
✓ VerifiedFDA multi-discipline review, p. 30Source ↗
Pivotal GLP studies
Cynomolgus monkey studies of 4, 13 (fertility) and 26 weeks
“The toxicity of cemiplimab was evaluated in the repeat dose toxicity studies of 4, 13 and 26-weeks duration in monkeys. The 13-week study was dedicated to evaluation of fertility endpoints.”